Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
15 Febrero 2022 - 3:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE
ACT OF 1934
BioDelivery Sciences
International, Inc.
(Name of Subject Company)
BioDelivery Sciences
International, Inc.
(Name of Persons Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
09060J106
(CUSIP Number of Class of Securities)
Jeffrey Bailey
Chief Executive Officer
4131 ParkLake Ave., Suite 225
Raleigh, NC 27612
(919) 582-9050
(Name, Address and Telephone Number, including
area code, of Agent For Service)
With copies to:
Robert E. Puopolo, Esq.
Blake Liggio, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, MA 02210
(617) 570-1000
(Name, address, and telephone numbers of person
authorized to receive notices and communications
on behalf of the persons filing statement)
x
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
The information set forth under Items 1.01, 5.03, 7.01 and 9.01 of
the Current Report on Form 8-K/A filed by BioDelivery Sciences International, Inc. on February 15, 2022 (including all exhibits attached
thereto) is incorporated herein by reference.
BioDelivery Sciences (NASDAQ:BDSI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BioDelivery Sciences (NASDAQ:BDSI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about BioDelivery Sciences International Inc (NASDAQ): 0 recent articles
Más de Biodelivery Sciences International Inc Artículos de Noticias